Choroidal melanoma therapy offers promising treatment option

Source: Healio, April 2019

HILADELPHIA — A choroidal melanoma therapy has been shown to reduce tumor thickness and preserve best corrected visual acuity in patients participating in a phase 1b/2 study, according to a speaker here.

AU-011 (Aura Biosciences) has been administered to 30 patients with choroidal melanoma, demonstrating 87% tumor control in subjects with a single cycle treatment up to 6 months, Carol L. Shields, MD, said at the Wills Eye Conference.

“This is a safe treatment for both single and multiple administrations. Inflammation is manageable, and we have seen reduction in tumor thickness. One case actually had fine needle aspiration biopsy at 8 months, and there was complete tumor necrosis. No melanoma was left in the needle biopsy,” Shields said.